Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):309-314. doi: 10.1016/j.bbcan.2017.06.004. Epub 2017 Jun 21.
A remarkable characteristic of majority of cancer cells is that, they fail to undergo apoptosis, which in turn confers them a survival advantage over normal cells. Targeted cancer therapy aims at disrupting the functions of proteins that play an important role during cancer progression. Antiapoptotic protein, BCL2, is one such protein that is highly upregulated in many cancers as compared to normal cells, making it an ideal target for cancer therapy. Although, several BCL2 targeting agents have been investigated over the past 30 years, very few have exhibited any clinical significance. This mini-review outlines a road map of existing BCL2 inhibitors and their relevance in treating cancer, and discusses potential strategies for future research with respect to BCL2 specific cancer therapy.
大多数癌细胞的一个显著特征是，它们无法进行细胞凋亡，这使它们相对于正常细胞具有生存优势。靶向癌症治疗旨在破坏在癌症进展过程中发挥重要作用的蛋白质的功能。抗凋亡蛋白 BCL2 就是这样一种蛋白质，与正常细胞相比，它在许多癌症中高度上调，使其成为癌症治疗的理想靶点。尽管过去 30 年来已经研究了几种 BCL2 靶向药物，但很少有药物表现出任何临床意义。这篇迷你综述概述了现有的 BCL2 抑制剂及其在治疗癌症方面的相关性，并讨论了针对 BCL2 特异性癌症治疗的未来研究的潜在策略。
